, it is not known how anxiety-provoking the recognition of personal risk status is for British women. Furthermore, there are no published data concerning the anxiety of women who know that they have a family history placing them at high risk but do not attend specialist clinics. This raises the question as to whether or not anxiety is prevalent throughout the entire population of 'at risk' women or if family history clinics see a selfselected group of the most anxious. It is also possible that attending a family history clinic exacerbates or alleviates anxiety. Furthermore, there may well be differences in the understanding of risk in women attending compared with those not attending a specialist clinic.
Awareness of the hereditary nature of breast cancer is increasing among those women who have relatives with breast cancer. Howe (1981) reported that 76% of 95 American women with a family history of breast cancer did not consider themselves to be at higher risk than the general population. Ten years later, the message seemed to have reached more American women: Kash et al. (1992) found only 24% of 'at risk' women felt that their risk was either low or nil. The picture is similar among British women. Evans et al. (1993) reported that 29% of 155 women attending a breast cancer family history clinic underestimated their personal risk.
Although there have been two American studies reporting high levels of anxiety in women with a family history of breast cancer attending a breast cancer family history clinic (Kash et al., 1992; Lerman and Croyle, 1994) , it is not known how anxiety-provoking the recognition of personal risk status is for British women. Furthermore, there are no published data concerning the anxiety of women who know that they have a family history placing them at high risk but do not attend specialist clinics. This raises the question as to whether or not anxiety is prevalent throughout the entire population of 'at risk' women or if family history clinics see a selfselected group of the most anxious. It is also possible that attending a family history clinic exacerbates or alleviates anxiety. Furthermore, there may well be differences in the understanding of risk in women attending compared with those not attending a specialist clinic.
Currently British women with a family history of breast cancer who are attending family history clinics are being offered the opportunity to participate in a chemoprevention trial. Following genetic counselling about breast cancer risk and the nature of the trial, consenting women are randomised to either tamoxifen or a placebo for 5 years. We report a study comparing anxiety in 99 women participating in the tamoxifen prevention trial with that found in 87 women with a family history who are not attending a specialist clinic and 86 women without a reported family history. The non-trial women were all recruited from the National Breast Screening Programme (NBSP). Consequently, all the women in the study have undergone the same potentially anxiety-provoking experience of mammography.
Method Subjects
Tamoxifen trial participants A total of 550 women are currently participating in the psychosocial arm of the chemoprevention trial of tamoxifen in women at high genetic risk of developing breast cancer. In the psychosocial study the impact that long-term tamoxifen has on quality of life variables is being assessed. One hundred of the trial participants recruited from the Royal Marsden Hospital family history clinic were randomly selected for the comparative study being reported here.
Women were referred to the Royal Marsden by their general practitioners and had therefore received some information about risk before their visit. At the clinic they underwent clinical examination and mammography, followed by genetic counselling. Eligible women with a greater than 4-fold risk were told about the chemoprevention trial. All this information was repeated on a detailed information sheet that they were required to read before giving informed consent to joining the prevention trial. National Breast Screening Programme participants A total of 131 women with a family history of breast cancer and 126 women without such a history were recruited from women attending for routine screening as part of the National Breast Screening Programme in south-east London. These women received no genetic counselling before recruitment. The women in all groups were aged 50 years or more.
Women were classified using the Registrar General Classification System according to their occupation: I, professional; II, semi professional; III, skilled; IV, unskilled and V, not classifiable. The final class V included housewives, students, voluntary counsellors and others with an occupation that did not fit the first four categories. Women participating in the prevention trial were more likely to be from groups I and II than women from the National Breast Screening Programme (chi-square test = 19.9, P< 0.0001), but as the majority of women were unclassifiable by occupation (V) these data are an unreliable means of establishing the social class of the groups.
Assessment measures All subjects were given the Spielberger trait anxiety inventory, a standardised clinical tool for measuring anxiety (Spielberger et al., 1983) , and a questionnaire examining women's understanding of: perception of risk in the general population; causality of breast lumps; the relationship between age and breast cancer risk; and other demographic and behavioural variables associated with breast cancer risk (Fallowfield et al., 1990) . Women were asked to indicate whether they believed the general population risk to be 1 in 100, 1 in 55 or 1 in 12. These questionnaires had been used in a previously reported study of breast cancer screening (Fallowfield et al., 1990) .
Trait anxiety was used as a measure of anxiety for two reasons. Firstly, having an increased risk of developing breast cancer is a permanent condition so any negative effect on anxiety would be expected to be consistent and long-term. Secondly, as women in the study returned their questionnaires by post, ensuring they completed them at the same time was impossible, rendering a measure of state anxiety (how you feel right now) inappropriate.
Procedure
Questionnaires were given to all women who consented to join the psychosocial arm of the tamoxifen prevention trial, at trial entry after mammography. They had been informed that the purpose of the psychosocial study was to assess the effect of tamoxifen on anxiety and other quality of life variables. Prepaid envelopes were provided for the return of the questionnaires.
Women at the national breast screening clinic were recruited into the study following their mammogram. They were given both questionnaires and asked to return them in prepaid envelopes. They were informed that the study aimed to monitor the impact of the screening programme on anxiety. Family history status was confirmed by the radiologist who routinely asked all women a number of sociodemographic and clinical questions including family history.
The entry criteria for women aged 50 or more to join the tamoxifen prevention trial were a mother or sister who has had breast cancer or two close relatives who have had breast cancer. The entry criterion for participation in the psychological study for women attending for routine screening mammography was at least one close maternal relative with breast cancer. Radiologists at the screening clinic did not have time to research family history in great detail. Therefore, it is possible that some women with a family history recruited from the NBSP would not have had sufficiently high risks to make them eligible for the tamoxifen prevention trial.
Trial participants and women from the screening programme were all given the questionnaires to take home and complete on the same day that they had their mammogram so time between mammography and completion of the questionnaires was similar for both.
Analysis
The data were analysed using the SPSS/PC statistical package. Initially, a stepwise regression analysis was carried out to identify any variables related to anxiety. Amongst the 91 accurate women, the 24 with a family history not attending a specialist clinic had significantly higher anxiety scores than the 47 with a history participating in the tamoxifen trial (Table I) . This is despite the less stringent criteria of family history used as a definition of 'high risk' for women from the NBSP. These data do not add support to the hypothesis that specialist clinics see a selfselected group of the most anxious. Women participating in the tamoxifen trial had similar anxiety scores to women without a family history attending for routine screening. This was true for women with accurate or inaccurate risk perceptions.
One explanation of the findings is that women with accurate risk perceptions who are highly anxious avoid specialist clinics. Alternatively, participation in the prevention programme or attendance at a specialist clinic may alleviate anxiety in 'high risk' women with accurate risk perceptions. Kash et al. (1992) and Lerman and Croyle, (1994) reported high levels of anxiety in American women attending a breast cancer family history clinic but not participating in any prevention programme which suggests it may be participation in the prevention programme rather than attendance at a clinic which is related to any alleviation of anxiety. However, there are no data from American 'at risk' women not attending any specialist clinic; they too may have higher levels of anxiety than those reported in American woman attending a history clinic.
The data reported in our study suggest that participation in the tamoxifen prevention programme, which requires regular screening and attendance at a family history clinic does not exacerbate anxiety and may even alleviate anxiety for some women.
